Belgium-based biotechnology company Union Chimique Belge (UCB) aims to commit fund in new research and development (R&D) facility in the UK.

The company expects to invest between 150 million to 200 million pounds ($190.9 million to $254.6 million) in its new R&D hub.

UCB, which currently employs across the UK and Ireland, will increase employment opportunities to 650 jobs especially in R&D positions.

The investment will go towards a precision cancer research partnership, involving U.S. genomic profiling assays manufacturer Foundation Medicine and a hospital specialized in oncology.